Medtronic (NYSE: MDT) delivered better-than-expected results for its fiscal fourth quarter on Wednesday, and the medical-device maker followed the news by projecting solid earnings and organic revenue growth for the year ahead. Investors responded quickly, sending shares higher in Wednesday trading.

Fourth-Quarter Results Clear the Bar

For the three months ended April 24, Medtronic posted adjusted earnings of $1.55 a share, down from $1.62 a year earlier but still ahead of the $1.54 consensus in a FactSet survey. Revenue, meanwhile, climbed 9.9% to $9.81 billion, comfortably topping the $9.62 billion analysts had expected. On an organic basis, which strips out currency swings and other one-time items, sales rose 6.6%.

The market liked what it saw. Medtronic shares advanced 4.9% on Wednesday, though they remain down 19% so far this year.

Management Strikes a Confident Tone

Company leadership framed the quarter as a launching point rather than a one-off. “We are pleased to have delivered results ahead of expectations on both revenue and EPS,” said Chief Financial Officer Thierry Pieton. He added that the company enters fiscal 2027 with strong momentum, a resilient operating foundation, and a clear path toward durable growth.

CEO Geoff Martha echoed that optimism. He pointed to continued strength across the company’s major businesses--including cardiac rhythm management, cranial and spinal technologies, and surgical--while emphasizing that Medtronic is building momentum in its highest-growth opportunities.

A Closer Look at the Segments

Beyond the headline numbers, the cardiovascular portfolio drove much of the quarter’s strength. Revenue there jumped 14% to $3.8 billion, lifted by a 22% surge in cardiac rhythm and heart-failure products. Diabetes also stood out, with revenue rising 15% to $837 million on the back of growth in insulin-pump and sensor technologies.

The remaining segments contributed steady gains as well. Neuroscience sales increased 5% to $2.75 billion, and medical surgical revenue advanced 8% to $2.39 billion.

Guidance Points to Continued Growth

Looking ahead, Medtronic guided to adjusted EPS of $5.90 to $6 for fiscal 2027, which would represent growth of 6.7% to 8.5%. That range sits just below the $6.05 analysts currently project. The company also expects foreign exchange to land somewhere between neutral and a 1% benefit.

On the top line, management forecast organic revenue growth of 6.8% to 7.3% for the full year--an acceleration from the 5.8% growth Medtronic delivered in fiscal 2026.

The Bottom Line

Taken together, the quarter and the outlook suggest a company regaining its footing. Even with shares still underwater for the year, Medtronic’s earnings beat, broad-based segment growth, and upbeat guidance give investors a clearer reason to watch how the next four quarters unfold.

The post Medtronic Beats Fiscal Q4 Estimates, Projects Stronger Full-Year Earnings appeared first on PRISM MarketView.

COMTEX_483590104/2927/2026-06-09T20:00:37